Copyright © Inderes 2011 - present. All rights reserved.

Revenio Group

18.62 EUR

-0.85 %

14,279 following
Corporate customer

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.85 %
+0.65 %
-16.87 %
-16.87 %
-18.69 %
-26.64 %
-47.49 %
-63.98 %
+880.00 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
496.8M EUR
Turnover
277.12K EUR
P/E (adj.) (26e)
21
EV/EBIT (adj.) (26e)
15.53
P/B (26e)
3.9
EV/S (26e)
3.86
Dividend yield-% (26e)
2.69 %
Coverage
Recommendation
Buy
Target price
24.00 EUR
Updated
12.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 12.02.2026

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
15.4
2026

General meeting '26

28.4
2026

Interim report Q1'26

6.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Revenio Q4'25 preview: Valuation reaches historic lows
Research by
Juha Kinnunen

Revenio Q4'25 preview: Valuation reaches historic lows

Revenio's valuation has fallen to a historically low level, as the industry faces concerns, especially after Zeiss's grim profit warning. We consider the concerns regarding Revenio to be exaggerated and estimate the company's earnings to be firmly on an upward trend this year.

Revenio Group
Revenio Q3'25: Q4 will decide this year too
Research by
Juha Kinnunen

Revenio Q3'25: Q4 will decide this year too

Revenio's Q3 earnings fell short of our overly optimistic expectations, but on the other hand, the Q4 outlook appears better than we anticipated. There have been no dramatic revisions in the outlook for the coming years, but the market is showing at least small signs of recovery.

Revenio Group
Forum discussions
Juha and I recorded a video about Revenio today. Juha defends Revenio’s Buy recommendation against my doubts. Inderes Onko Revenio arvoansa? - Inderes Aika: 18.03.2026 klo 16.20 Revenion osake on kosahtanut 75 % huipuistaan. Onko Reveniolla takana vain loistava menneisyys?
3/18/2026, 2:33 PM
by Iikka Numminen
41
I have been a Revenio shareholder for a very long time, but nowadays its weight in my portfolio is quite small – and that is not exactly a coincidence. The case seems to be stalling. There is growth, but not the kind that this story should be producing. Clearly, more was expected...
3/18/2026, 3:01 PM
by mutu_sijoittaja
34
However, this point is interesting: 20. Amendment of Article 4 of the Articles of Association The Board of Directors proposes that Article 4 of the Articles of Association be amended such that the maximum number of ordinary members of the Board of Directors changes from seven (7)...
3/23/2026, 2:55 PM
by Sissos
31
Apparently, CEO Toijala has enough time to focus outside of Revenio, as he is a candidate for QT’s board of directors. In my opinion, in smaller companies, resources are so limited that there would be plenty to invest in one’s own company, be it customer relationships, new market...
3/20/2026, 7:26 AM
by Opa
25
At Optomed, the company doesn’t disclose anything itself, so investors have to find all the information on their own. As a result, every trivial LinkedIn gathering and back-slapping event is interpreted as a roaring success, which naturally leads to grumbling and speculation.
3/13/2026, 3:39 PM
by Jekkku
21
Sometimes I wonder why Revenio generates so little discussion on the forum compared to, say, Optomed. With Optomed, every little scrap of information available online is thoroughly picked apart. Is it because of this fallen and stagnant share price, or what?
3/13/2026, 2:59 PM
by MTES
13
This is a pretty convincing picture. Halfway to becoming a Dividend Aristocrat. Are the years when the dividend remained the same counted, or only the years when the dividend increased? Well, they certainly grow. But what about extra dividends?
3/23/2026, 3:16 PM
by Sissos
12
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.